又一腫瘤免疫抗體進入臨牀!君實生物(1877.HK/688180.SH)申報TIGIT抗體臨牀獲受理
格隆匯11月25日丨君實生物(1877.HK/688180.SH)TIGIT抗體JS006的臨牀試驗申請今日獲得NMPA受理,為君實在PD-1,PD-L1,BTLA以後又一進入臨牀階段的腫瘤免疫抗體。近期君實生物動作頻頻,PD-1獲得美國FDA突破療法,一線鼻咽癌中期分析達到臨牀終點,引進IL-2,與Revitope簽訂合作協議開發5個雙抗原全新品種,與百奧賽圖合作利用其全人源抗體轉基因小鼠平台開發全人源抗體等。君實生物與中微所、禮來聯合開發的新冠中和抗體也在中美緊張的臨牀試驗中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.